Document is current

Article History

Received: 16 January 2025

Accepted: 10 July 2025

First Online: 19 July 2025

Declarations

:

: The study was conducted in accordance with the principles of the Declaration of Helsinki. The study was approved by the Providence and University of California Los Angeles Health Institutional Review Boards, who determined written informed consent was not required for analyses of a retrospective, limited dataset, and was conducted according to Reporting of Observational Studies in Epidemiology guidelines.

: Not applicable.

: SBN is supported by NIH research grants R01MD014712, RF00250-2022-0038, U2CDK129496 and P50MD017366, CDC project number 75D301-21-P-12254, and the Terasaki Institute of Biomedical Innovation; receives research support from Travere Therapeutics Inc. for the submitted work; and personal fees and other support from AstraZeneca, Bayer AG, Gilead, Novo Nordisk and Boehringer Ingelheim/Lilly. LMK is supported by an NIH research grant OT2OD032581 and CDC project number 75D301-21-P-12254 and 75D301-23-C-18264; and reports other support from Travere Therapeutics Inc. for the submitted work, and Benaroya Research Institute outside of the submitted work. CRJ is supported by an NIH research grant R01MD014712, OT2OD032581 and CDC project numbers 75D301-21-P-12254 and 75D301-23-C-18264; and reports other support from the Doris Duke Charitable Foundation and Benaroya Research Institute outside of the submitted work, and Travere Therapeutics Inc. for the submitted work. KBD is supported by NIH research grants R01MD014712, OT2OD032581 and CDC project numbers 75D301-21-P-12254 and 75D301-23-C-18264; and reports other support from the Doris Duke Charitable Foundation and Benaroya Research Institute outside of the submitted work, and Travere Therapeutics Inc. for the submitted work. RZA is supported by NIH research grants OT2HL161847, OT2OD032581, U24TR001608 and CDC project numbers 75D301-21-P-12254 and 75D301-23-C-18264; and reports other support from Travere Therapeutics Inc. for the submitted work, the Doris Duke Charitable Foundation, Benaroya Research Institute Bayer AG, AstraZeneca, The George Institute for Global Health, CareDx, and KBP BioSceinces outside the submitted work, and personal fees from Boehringer Ingelheim; Bayer Pharmaceuticals, and Eli Lilly. CLR is supported by NIH research grants OT2OD032581 and reports other support from the Doris Duke Charitable Foundation and Benaroya Research Institute outside the submitted work, and Travere Therapeutics Inc for the submitted work. JJN is supported by NIH research grant OT2OD032581 and a research grant from the American College of Clinical Pharmacy, and reports personal fees and other support from Bayer AG, Sanofi, Novo Nordisk, Boehringer Ingelheim, Eli Lilly, Proteomics International, and Dexcom outside the submitted work. MEB is an employee of Benefit Consulting PTY LTD, Brisbane, Australia and has received consulting fees from Travere Therapeutics, Inc. and Amgen, Inc. WG is an employee of Travere Therapeutics Inc. KCN is supported in part by NIH research grants UL1TR001881, P30AG021684, U2CDK129496 and P50MD017366, and reports personal fess from Atlantis Dialysis Inc. and AstraZeneca. KRT is supported by NIH research grants R01MD014712, U2CDK114886, UL1TR002319, U54DK083912, U01DK100846, OT2HL161847, UM1AI109568, OT2OD032581, and CDC project numbers 75D301-21-P-12254 and 75D301-23-C-18264. She has also received investigator-initiated grant support from Travere Therapeutics, Inc. for the submitted work and from Bayer Pharmaceuticals, the Doris Duke Charitable Foundation, and Benaroya Research Institute outside of the submitted work. She reports consultancy fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novo Nordisk and Pfizer; and speaker fees from Novo Nordisk.